Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sonya L Cyr

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Pediatric Dermatology|February 3, 2024
A case series of live attenuated vaccine administration in dupilumab-treated children with atopic dermatitisElaine C Siegfried, Lara Wine Lee, Jonathan M Spergel, et al.
Dermatology and Therapy|March 19, 2026
Correction: Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous UrticariaGil Yosipovitch, Brian S Kim, John Y Koo, et al.
Vaccine|October 26, 2005
Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infectionTaff Jones, Jeffrey J Adamovicz, Sonya L Cyr, et al.
Dermatology and Therapy|November 22, 2025
Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous UrticariaGil Yosipovitch, Brian S Kim, John Y Koo, et al.
American Journal of Clinical Dermatology|June 10, 2023
Dupilumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III TrialElaine C Siegfried, Michael J Cork, Norito Katoh, et al.
Advances in Therapy|November 1, 2022
No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with DupilumabAndrew Blauvelt, Andreas Wollenberg, Lawrence F Eichenfield, et al.
Paediatric Drugs|January 24, 2024
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic DermatitisAmy S Paller, Elaine C Siegfried, Michael J Cork, et al.
Pediatric Dermatology|January 27, 2022
Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis-A pooled analysis of trial dataAmy S Paller, Lisa A Beck, Andrew Blauvelt, et al.
Pediatric Dermatology|November 12, 2024
Low Infection Rates With Long-Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open-Label Extension StudyAmy S Paller, Michele Ramien, Michael J Cork, et al.
Dermatology and Therapy|December 1, 2025
Dupilumab Improves Health-Related Quality of Life in Omalizumab-Naïve Patients with Chronic Spontaneous UrticariaAna M Giménez-Arnau, Thomas B Casale, Gil Yosipovitch, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Pediatric Dermatology|February 3, 2024
A case series of live attenuated vaccine administration in dupilumab-treated children with atopic dermatitisElaine C Siegfried, Lara Wine Lee, Jonathan M Spergel, et al.
Dermatology and Therapy|March 19, 2026
Correction: Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous UrticariaGil Yosipovitch, Brian S Kim, John Y Koo, et al.
Vaccine|October 26, 2005
Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infectionTaff Jones, Jeffrey J Adamovicz, Sonya L Cyr, et al.
Dermatology and Therapy|November 22, 2025
Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous UrticariaGil Yosipovitch, Brian S Kim, John Y Koo, et al.
American Journal of Clinical Dermatology|June 10, 2023
Dupilumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III TrialElaine C Siegfried, Michael J Cork, Norito Katoh, et al.
Advances in Therapy|November 1, 2022
No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with DupilumabAndrew Blauvelt, Andreas Wollenberg, Lawrence F Eichenfield, et al.
Paediatric Drugs|January 24, 2024
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic DermatitisAmy S Paller, Elaine C Siegfried, Michael J Cork, et al.
Pediatric Dermatology|January 27, 2022
Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis-A pooled analysis of trial dataAmy S Paller, Lisa A Beck, Andrew Blauvelt, et al.
Pediatric Dermatology|November 12, 2024
Low Infection Rates With Long-Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open-Label Extension StudyAmy S Paller, Michele Ramien, Michael J Cork, et al.
Dermatology and Therapy|December 1, 2025
Dupilumab Improves Health-Related Quality of Life in Omalizumab-Naïve Patients with Chronic Spontaneous UrticariaAna M Giménez-Arnau, Thomas B Casale, Gil Yosipovitch, et al.
Pageof 3